<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00249249</url>
  </required_header>
  <id_info>
    <org_study_id>NK-104-301</org_study_id>
    <secondary_id>EudraCT number 2005-001000-39</secondary_id>
    <nct_id>NCT00249249</nct_id>
  </id_info>
  <brief_title>Study to Compare the Efficacy of Pitavastatin With That of Atorvastatin in Lowering Cholesterol Levels</brief_title>
  <official_title>Study of Pitavastatin 2 mg vs. Atorvastatin 10 mg and Pitavastatin 4 mg vs. Atorvastatin 20 mg (Following Up Titration) in Patients With Primary Hypercholesterolemia or Combined Dyslipidemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kowa Research Europe</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Kowa Research Europe</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the efficacy of pitavastatin with that of
      atorvastatin.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Following a wash-out dietary lead-in period, patients will receive either Atorvastatin or
      Pitavastatin during 12 weeks, in order to establish the efficacy of pitavastatin in reducing
      cholesterol levels.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2005</start_date>
  <completion_date type="Actual">November 2006</completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percent Change From Baseline Low Density Lipoprotein-cholesterol (LDL-C) at Week 12</measure>
    <time_frame>Baseline to 12 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Total Cholesterol (TC)</measure>
    <time_frame>Baseline to 12 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in High Density Lipoprotein Cholesterol (HDL-C)</measure>
    <time_frame>Baseline to 12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>TC:HDL-C Ratio</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Triglycerides (TG)</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Non-HDL:HDL Ratio</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apolipoprotein B (Apo B)</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apolipoprotein-A1 (Apo-A1)</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apo-B:Apo-A1 Ratio</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>High Sensitivity C-reactive Protein (Hs-CRP) at 12 Weeks</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Oxidized LDL at 12 Weeks</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>National Cholesterol Education Program [NCEP]LDL-C Target Attainment</measure>
    <time_frame>up to 12 weeks</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">830</enrollment>
  <condition>Primary Hypercholesterolemia</condition>
  <condition>Dyslipidemia</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pitavastatin</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atorvastatin</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Males and females (age 18-75 years).

          -  Non-pregnant, non-lactating females

          -  Women of child bearing potential should use sustained contraceptive preparations or an
             approved mechanical contraceptive method.

          -  Eligible and able to participate and have given informed consent

          -  Must have been following a restrictive diet and does not eat or drink grapefruit

          -  Diagnosis of primary hypercholesterolemia or combined dyslipidemia

          -  Available for every clinic visit, which will occur in the morning.

        Exclusion Criteria:

          -  Homozygous familial hypercholesterolemia or familial hypoalphalipoproteinemia

          -  Conditions which may cause secondary dyslipidemia.

          -  Condition which might significantly alter the absorption, distribution, metabolism, or
             excretion of any drug.

          -  History of pancreatic injury or pancreatitis, or impaired pancreatic function/injury

          -  Liver injury

          -  Impaired renal function

          -  Current obstruction of the urinary tract or difficulty in voiding due to mechanical as
             well as inflammatory conditions, which is likely to require intervention during the
             course of the study or is regarded as clinically meaningful by the investigator

          -  Serum creatine kinase (CK) &gt;5 x upper limit of the reference range (ULRR).

          -  Uncontrolled hypothyroidism

          -  Severe acute illness or severe trauma in the last 3 months

          -  Major surgery, 3 months prior to Visit 1

          -  Significant cardiovascular disease (CVD) prior to randomization

          -  Evidence of symptomatic heart failure, gross cardiac enlargement; significant heart
             block or cardiac arrhythmias. History of uncontrolled complex ventricular arrhythmias,
             uncontrolled atrial fibrillation/flutter or uncontrolled supraventricular tachycardias
             with a ventricular response rate of &gt;100 beats per minute at rest.

          -  Left ventricular (LV) ejection fraction &lt; 0.25

          -  History of symptomatic cerebrovascular disease

          -  Conditions at the discretion of the investigator

          -  Known HIV infection

          -  Poorly controlled or uncontrolled hypertension.

          -  Known muscular or neuromuscular disease of any type

          -  Neoplastic disease

          -  Drug abuse or continuous consumption of more than 65 mL pure alcohol per day

          -  Exposure to any investigational new drug within 30 days of study entry or ingestion of
             any drug known to be toxic to a major organ system

          -  Current or recent use of supplements known to alter lipid metabolism

          -  Hypersensitivity reactions to other HMG-CoA reductase inhibitors

          -  Concomitant medication not permitted

          -  Resistant to lipid-lowering medications. Known hypersensitivity or intolerance to any
             lipid lowering agent

          -  Excessive obesity

          -  Regular clinic attendance in the morning impractical

          -  Signs of mental dysfunction or other factors likely to limit ability to cooperate
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dragos Budinski, Med Dr.</last_name>
    <role>Study Director</role>
    <affiliation>Kowa Research Europe</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Y Forskning, Bispebjerg Hospital</name>
      <address>
        <city>Copenhagen Nv</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Copenhagen University Hospital</name>
      <address>
        <city>Copenhagen</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Center</name>
      <address>
        <city>Copenhagen</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Frederiks Hospital, Kardiologisk</name>
      <address>
        <city>Frederiksberg</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kolesterollaboratoriet</name>
      <address>
        <city>Hellerup</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CCBR A/S</name>
      <address>
        <city>Vejle</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Geri-Med Oy</name>
      <address>
        <city>Helsinki</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kaisaniemen Laakariasema</name>
      <address>
        <city>Helsinki</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>keravan Laakarikeskus</name>
      <address>
        <city>Helsinki</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SOK-tyoterveyshuolto</name>
      <address>
        <city>Tampere</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>TYKS University Hospital</name>
      <address>
        <city>Turku</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kardiologische Gemeinschaftspraxis Prof. Reifart</name>
      <address>
        <city>Bad Soden/Taunus</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Praxis Dr. Boenninghoff</name>
      <address>
        <city>Beckum</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gemeinschaftspraxis am Bahnhof</name>
      <address>
        <city>Berlin-Spandau</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinische Forschung Berlin Mitte</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pharmakologisches Studienzentum Chemnitz</name>
      <address>
        <city>Chemnitz</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GWT-TUK mbH, Zentrum fur Klinische Studien</name>
      <address>
        <city>Dresden</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Internistische Diabetische Schwerpunktpraxis Dr.</name>
      <address>
        <city>Frankfurt Am Main</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gemeinschaftspraxis Dr. Krause, Th. Menke</name>
      <address>
        <city>Goch</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinische Forschung Hamburg</name>
      <address>
        <city>Hamburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Innere Medizin I/Medizinische Klinik</name>
      <address>
        <city>Heidelberg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gemeinschaftspraxis H. Holz Dr. Med, K. W. Klingl</name>
      <address>
        <city>Lampertheim</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ZET-Studien GmbH Leipzig</name>
      <address>
        <city>Leipzig</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Internistische Gemeinschaftspraxis</name>
      <address>
        <city>Mainz</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Praxis Dr. Wachter</name>
      <address>
        <city>Mannheim</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gemeinschaftspraxis Melcherstaette</name>
      <address>
        <city>Melcherstaette</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gemeinschaftspraxis Dr. Senftleber, Dr. Kohler</name>
      <address>
        <city>Messkirch</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Praxisgemeinschaft im Kleinen Biergrund</name>
      <address>
        <city>Offenbach/M</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gemeinschaftspraxis Drs. Mockesch</name>
      <address>
        <city>Weinheim</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Intermed Institud Fur Klinische Forschung und Arzn</name>
      <address>
        <city>Wiesbaden</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gemeinschaftspraxis Dr. Emden, Frank Drewes</name>
      <address>
        <city>Worpswede</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Apollo Hospital</name>
      <address>
        <city>Andhra Pradesh</city>
        <zip>500033</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Care Hospital</name>
      <address>
        <city>Andhra Pradesh</city>
        <zip>500034</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>School of Diabetology, Nizam Institute of Medical Sciences</name>
      <address>
        <city>Andhra Pradesh</city>
        <zip>500082</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bhagwan Mahaveer Jain Heart Centre</name>
      <address>
        <city>Bangalore</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sri Ramachandra Medical College Hospital</name>
      <address>
        <city>Chennai</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Heart Care Clinic</name>
      <address>
        <city>Gujarat</city>
        <zip>380054</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Apollo Hospitals</name>
      <address>
        <city>Hyderabaad</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CARE Group of Hospitals</name>
      <address>
        <city>Hyderabaad</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. John's Medical College Hospital,</name>
      <address>
        <city>Karnataka</city>
        <zip>560034</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. John's Medical College Hospital</name>
      <address>
        <city>Karnataka</city>
        <zip>560034</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bathia Hospital</name>
      <address>
        <city>Maharashtra</city>
        <zip>400007</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>LTMMC &amp; General Hospital</name>
      <address>
        <city>Maharashtra</city>
        <zip>400022</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sir J. J. Group of Hospitals</name>
      <address>
        <city>Maharashtra</city>
        <zip>400027</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>King Edward Medical College &amp; Hospital</name>
      <address>
        <city>Maharashtra</city>
        <zip>411001</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ruby Hall Clinic</name>
      <address>
        <city>Maharashtra</city>
        <zip>411001</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lokmanya Hospital</name>
      <address>
        <city>Maharashtra</city>
        <zip>411033</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>PD Hinduja Hospital</name>
      <address>
        <city>Mumbai</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Apollo Hospital</name>
      <address>
        <city>New Delhi</city>
        <zip>110044</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sir Gagaram Hospital</name>
      <address>
        <city>New Delhi</city>
        <zip>110060</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Apollo Hospital</name>
      <address>
        <city>Tamil Nadu</city>
        <zip>600006</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Cardiology</name>
      <address>
        <city>Tamil Nadu</city>
        <zip>641004</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Internal Medicine, Soroka Medical Center</name>
      <address>
        <city>Beersheva</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Internal Medicine A, Rambam Medical Center</name>
      <address>
        <city>Haifa</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Internal Medicine, Wolfson Medical Center</name>
      <address>
        <city>Holon</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Center for Research, Hadassah University Hospital</name>
      <address>
        <city>Jerusalem Ein Kerem</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Meir Hospital</name>
      <address>
        <city>Kfar Saba</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Medicine, Hadassah Medical Center</name>
      <address>
        <city>Mount Scopus Jerusalem</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Internal Medicine, Rivka Sieff Medical Center</name>
      <address>
        <city>Safed</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institute of Metabolic Diseases</name>
      <address>
        <city>Tel Aviv</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institute of Lipid &amp; Atherosclerosis Research</name>
      <address>
        <city>Tel Hashomer</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dipartimento di Medicina Clinica e Biotecnologia Applicata</name>
      <address>
        <city>Bologna</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro di Ricerca Clinica</name>
      <address>
        <city>Chieti</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gerontologia e Geriatria - Universita degli Studi</name>
      <address>
        <city>Ferrara</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dipartimento di Medicina Interna DIMI</name>
      <address>
        <city>Genova</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universita di Modena e Reggio Emilia, Policlinico</name>
      <address>
        <city>Modena</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dipartimento di Medicina Clinica e Sperimentale</name>
      <address>
        <city>Napoli</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medicina Clinica e delle Patologie Emergenti</name>
      <address>
        <city>Palermo</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dipartimento di Medicina Interna e Scienze Biomediche</name>
      <address>
        <city>Parma</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>U.O Malattie Metaboliche e Diabetologia</name>
      <address>
        <city>Treviglio</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliero-Universitaria</name>
      <address>
        <city>Trieste</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Andromed Breda</name>
      <address>
        <city>Breda</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Middellaan 5</name>
      <address>
        <city>Breda</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Andromed Eindhoven</name>
      <address>
        <city>Eindhoven</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bomanshof 8</name>
      <address>
        <city>Eindhoven</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Andromed Noord</name>
      <address>
        <city>Groningen</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Damsterdiep 9</name>
      <address>
        <city>Groningen</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vasculair Onderzoek Centrum Hoorn</name>
      <address>
        <city>Hoorn</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Andromed Leiden</name>
      <address>
        <city>Leiden</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Doezastraat 1</name>
      <address>
        <city>Leiden</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Andromed Nijmegen</name>
      <address>
        <city>Nijmegen</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kamerlingh Onnesstraat 16-18</name>
      <address>
        <city>Nijmegen</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Andromed Rotterdam</name>
      <address>
        <city>Rotterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mathenesserlaan 247</name>
      <address>
        <city>Rotterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Albert Schweitzer Ziekenhuis</name>
      <address>
        <city>Sliedrecht</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Andromed Oost</name>
      <address>
        <city>Velp</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Reigerstraat 30</name>
      <address>
        <city>Velp</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rivierenland Tiel</name>
      <address>
        <city>Wp Tiel</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Andromed Zoetermeer</name>
      <address>
        <city>Zoetermeer</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Parkdreef 142</name>
      <address>
        <city>Zoetermeer</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Volvat Medisinske Senter</name>
      <address>
        <city>Fredrikstad</city>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nyomen Legekontor</name>
      <address>
        <city>Kongsberg</city>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Radhuset Spesialistsenter</name>
      <address>
        <city>Oslo</city>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rikshospitalet - University Hospital</name>
      <address>
        <city>Oslo</city>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Skedsmo Medisinske Senter A.S.</name>
      <address>
        <city>Skedsmokorset</city>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Podlaski Osrodek Kardiologii</name>
      <address>
        <city>Bialystok</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NZOZ GCP Dobra Praktyka Lekaska</name>
      <address>
        <city>Gruziadz</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NZOZ Terapia Optima</name>
      <address>
        <city>Katowice</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NZOZ Esculap, Przychodnia Lekary Rodzinnych</name>
      <address>
        <city>Losice</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NZOZ Centrum, Poradnia Kardiologiczna</name>
      <address>
        <city>Siedlce</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Spec. Gab. Lek. Internistyczno-Kardiologicznly</name>
      <address>
        <city>Tarnow</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Woj.Szp.Spec.Nr 1 im. Prof. J. Gasinskiego</name>
      <address>
        <city>Tychy</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instytut Zywnosci i Zywienia</name>
      <address>
        <city>Warszawa</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lecznica PROSEN SMO</name>
      <address>
        <city>Warszawa</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Szpital Wolski im. Dr A. Gostynskiej</name>
      <address>
        <city>Warszawa</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kemerovo Cardiology Dispensary</name>
      <address>
        <city>Kemerovo</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Central Clinical Hospital 1 of RZD</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>City Clinical Hospital 23</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>City Clinical Hospital 64</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Federal State Institution Out-Patient Clinic ï€£3 of Russian Federation of Presidentâ€™s Management</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Federal State Institution Outpatient Clinic ï€£3 of Russian Federation of Presidentâ€™s Management</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Moscow City Clinical Hospital 68</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Moscow Regional Research Clinic Institute n.a.M.F.Vladimirov, Department of Therapy</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>State Educational Institution of Higher Professional Education â€œMoscow State University of Medicine and Dentistry of Federal Agency of Health Care and Social Developmentâ€�, Department of Internal Diseases and Rheumatology based at City Clinica</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>State Educational Institution of Higher Professional Education â€œMoscow State University of Medicine and Dentistry of Federal Agency of Health Care and Social Developmentâ€�, Hospital Therapy Department # 1 based at City Clinical Hospital # 40</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>State Educational Institution of Higher Professional Education â€œMoscow State University of Medicine and Dentistry of Federal Agency of Health Care and Social Developmentâ€�, Hospital Therapy Department #1 based at City Clinical Hospital # 52</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>State Educational Institution of Higher Professional Education â€œRussian State Medical University Federal Agency of Health Care and Social Developmentâ€�, Department of Polyclinic Therapy based at Diagnostic Center # 1</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>State Educational Institution of Higher Professional Education â€œRussian State Medical University Federal Agency of Health Care and Social Developmentâ€�, Department of Therapy based at City Hospital # 4</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>State Educational Institution of Higher Professional Education â€œRussian State Medical University of Federal Agency of Health Care and Social Developmentâ€�, Department of Hospital Therapy #1 based at City Clinical Hospital #15, Cardiology Dept</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>State Institution â€œResearch Institute of Physical and Chemical Medicineâ€� of Federal Agency of Health Care and Social Development, Laboratory of Clinical Cardiology based at Bauman City Hospital # 29</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>State Institution â€œRussian Cardiology Research Complexâ€� of Federal Agency of Health Care and Social Development, Myasnikov Clinical Cardiology Institute, Department of Hemodialysis and Plasmapheresis</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>State Research Center for Preventive Medicine</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novosibirsk Reg. Clinical Cardiology Dispensary</name>
      <address>
        <city>Novosibirsk</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Central Medical Unit 122, St. Pb</name>
      <address>
        <city>Saint Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Hospital of Russian Academy of Sciences</name>
      <address>
        <city>Saint Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Consulting and Diagnostic Center 85</name>
      <address>
        <city>Saint Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Krestovsky Island Medical Institute</name>
      <address>
        <city>Saint Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pokrovskaya City Hospital</name>
      <address>
        <city>Saint Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Petersburg State Medical Institution â€œOut-patient Clinic # 109â€�</name>
      <address>
        <city>Saint Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Petersburg State Medical Institution â€œOutpatient Clinic # 109â€�</name>
      <address>
        <city>Saint Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Petersburg State Medical Institution â€œPokrovskaya City Hospitalâ€�, Cardiology Department #2</name>
      <address>
        <city>Saint Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>State Educational Institution of Higher Professional Education, â€œSaint-Petersburg State Medical University n.a.Academician I.P.Pavlov of Federal Agency of Health Care and Social Developmentâ€�, Chair and Department of Faculty Therapy</name>
      <address>
        <city>Saint Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>State Educational Institution of Higher Professional Education, â€œSaint-Petersburg State Medical University n.a.Academician I.P.Pavlov of Federal Agency of Health Care and Social Developmentâ€�, Institute of Cardiovascular Diseases</name>
      <address>
        <city>Saint Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clinico S. Juan de Alicante</name>
      <address>
        <city>San Juan</city>
        <state>Alicante</state>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clinic i Provincial</name>
      <address>
        <city>Villaroel</city>
        <state>Barcelona</state>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de San Vicente</name>
      <address>
        <city>Alicante</city>
        <zip>03690</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Santa Creu I Sant Pau,</name>
      <address>
        <city>Barcelona</city>
        <zip>08025</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Santa Creu I Sant Pau</name>
      <address>
        <city>Barcelona</city>
        <zip>08025</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de Bellvitge</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Vall d'Hebron</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Reina Sofia</name>
      <address>
        <city>Cordoba</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Ramon y Cajal</name>
      <address>
        <city>Madrid</city>
        <zip>28000</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro de Especialidades Pedro Gonzalez Bueno</name>
      <address>
        <city>Madrid</city>
        <zip>28037</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fundacion Jimenez Diaz</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clinico San Carlos</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro de Salud de Ventanielles</name>
      <address>
        <city>Oviedo</city>
        <zip>33010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Marques de Valdecilla</name>
      <address>
        <city>Santander</city>
        <zip>3908</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clinico Universitario de Santiago</name>
      <address>
        <city>Santiago de Compostela</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Virgen del Roci-o</name>
      <address>
        <city>Sevilla</city>
        <zip>41013</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Dr. Peset</name>
      <address>
        <city>Valencia</city>
        <zip>46017</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clinico Lozano Blesa</name>
      <address>
        <city>Zaragoza</city>
        <zip>50009</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Miguel Servet</name>
      <address>
        <city>Zaragoza</city>
        <zip>50009</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Angelholms Sjukhus, Medicinkliniken</name>
      <address>
        <city>Angelhom</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sahlgrenska University Hospital, Intermedicin</name>
      <address>
        <city>Gothenburg</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hjartmottagningen</name>
      <address>
        <city>Helsingborg</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lakarcentrum Nyponet</name>
      <address>
        <city>Karineholm</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medicinkliniken</name>
      <address>
        <city>Ludvika</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Huslakaren i Sandviken</name>
      <address>
        <city>Sandviken</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Narsjukhuset Sandviken, Kardiologlab, Medicin</name>
      <address>
        <city>Sandviken</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hjart &amp; Karlcenter</name>
      <address>
        <city>Sodertalje</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Karolinska Universitetssjukhuset</name>
      <address>
        <city>Stockholm</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hjarthuset AB</name>
      <address>
        <city>Varberg</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oldfield Surgery</name>
      <address>
        <city>Bath</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St James's Surgery</name>
      <address>
        <city>Bath</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St Michael's Partnership</name>
      <address>
        <city>Bath</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Pulteney Practice</name>
      <address>
        <city>Bath</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Birmingham Clinical Research Centre</name>
      <address>
        <city>Birmingham</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stonehill Medical Center</name>
      <address>
        <city>Bolton</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Avondale Surgery</name>
      <address>
        <city>Chesterfield</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chorley Clinical Research Centre</name>
      <address>
        <city>Chorley</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saltash Health Center</name>
      <address>
        <city>Cornwall</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gomersal Lane Surgery</name>
      <address>
        <city>Dronfield</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Townhead Research</name>
      <address>
        <city>Irvine</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Crosby Clinical Research Centre</name>
      <address>
        <city>Liverpool</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Symons Medical Center</name>
      <address>
        <city>Maidenhead</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Manchester Clinical Research Centre</name>
      <address>
        <city>Manchester</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Greenwood Medical Center</name>
      <address>
        <city>Nottingham</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Knowle House Surgery</name>
      <address>
        <city>Plymouth</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Reading Clinical Research Centre</name>
      <address>
        <city>Reading</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Elm Lane Surgery</name>
      <address>
        <city>Sheffield</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Burngreave Surgery</name>
      <address>
        <city>Sheffield</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Brook Lane Surgery</name>
      <address>
        <city>Southampton</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St Helier Hospital</name>
      <address>
        <city>Surrey</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Box Surgery</name>
      <address>
        <city>Wiltshire</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bradford Road Medical Center</name>
      <address>
        <city>Wiltshire</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Eastleigh Surgery</name>
      <address>
        <city>Wiltshire</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lovemead Group Practice</name>
      <address>
        <city>Wiltshire</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rowden Medical Partnership</name>
      <address>
        <city>Wiltshire</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St Chad's Surgery</name>
      <address>
        <city>Wiltshire</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Health Centre</name>
      <address>
        <city>Wiltshire</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Porch Surgery</name>
      <address>
        <city>Wiltshire</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Burns Medical Practice</name>
      <address>
        <city>Yorkshire</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
    <country>Finland</country>
    <country>Germany</country>
    <country>India</country>
    <country>Israel</country>
    <country>Italy</country>
    <country>Netherlands</country>
    <country>Norway</country>
    <country>Poland</country>
    <country>Russian Federation</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>January 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 4, 2005</study_first_submitted>
  <study_first_submitted_qc>November 4, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 7, 2005</study_first_posted>
  <results_first_submitted>August 26, 2009</results_first_submitted>
  <results_first_submitted_qc>November 13, 2009</results_first_submitted_qc>
  <results_first_posted type="Estimate">December 16, 2009</results_first_posted>
  <last_update_submitted>January 7, 2010</last_update_submitted>
  <last_update_submitted_qc>January 7, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 12, 2010</last_update_posted>
  <responsible_party>
    <name_title>Neil Hounslow, MD</name_title>
    <organization>Kowa Research Europe, Ltd.</organization>
  </responsible_party>
  <keyword>hypercholesterolemia</keyword>
  <keyword>dyslipidemia</keyword>
  <keyword>kowa</keyword>
  <keyword>KRE</keyword>
  <keyword>pitavastatin</keyword>
  <keyword>NK-104</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypercholesterolemia</mesh_term>
    <mesh_term>Dyslipidemias</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atorvastatin Calcium</mesh_term>
    <mesh_term>Pitavastatin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>First Patient In: 4 October 2005 Last Patient Out: 8 November 2006 A total of 39 investigators at 39 sites in India, Russia, Spain and Denmark received IRB approval to participate in this study and screened and randomized patients.</recruitment_details>
      <pre_assignment_details>Patients with major protocol violations were identified programmatically prior to unblinding to determine who should be excluded from the per protocol population.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Pitavastatin 2 mg QD</title>
          <description>Pitavastatin 2 mg daily</description>
        </group>
        <group group_id="P2">
          <title>Atorvastatin 10 mg QD</title>
          <description>Atorvastatin 10 mg daily</description>
        </group>
        <group group_id="P3">
          <title>Pitavastatin 4 mg QD</title>
          <description>Pitavastatin 4 mg daily</description>
        </group>
        <group group_id="P4">
          <title>Atorvastatin 20 mg QD</title>
          <description>Atorvastatin 20 mg daily</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="321"/>
                <participants group_id="P2" count="103"/>
                <participants group_id="P3" count="303"/>
                <participants group_id="P4" count="103"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Safety Population</title>
              <participants_list>
                <participants group_id="P1" count="316">All randomized patients who received at least one dose of study treatment.</participants>
                <participants group_id="P2" count="102">All randomized patients who received at least one dose of study treatment.</participants>
                <participants group_id="P3" count="300">All randomized patients who received at least one dose of study treatment.</participants>
                <participants group_id="P4" count="103">All randomized patients who received at least one dose of study treatment.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="301"/>
                <participants group_id="P2" count="98"/>
                <participants group_id="P3" count="288"/>
                <participants group_id="P4" count="100"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="15"/>
                <participants group_id="P4" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Pitavastatin 2 mg QD</title>
          <description>Pitavastatin 2 mg daily</description>
        </group>
        <group group_id="B2">
          <title>Atorvastatin 10 mg QD</title>
          <description>Atorvastatin 10 mg daily</description>
        </group>
        <group group_id="B3">
          <title>Pitavastatin 4 mg QD</title>
          <description>Pitavastatin 4 mg daily</description>
        </group>
        <group group_id="B4">
          <title>Atorvastatin 20 mg QD</title>
          <description>Atorvastatin 20 mg daily</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="316"/>
            <count group_id="B2" value="102"/>
            <count group_id="B3" value="300"/>
            <count group_id="B4" value="103"/>
            <count group_id="B5" value="821"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="219"/>
                    <measurement group_id="B2" value="75"/>
                    <measurement group_id="B3" value="207"/>
                    <measurement group_id="B4" value="73"/>
                    <measurement group_id="B5" value="574"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="97"/>
                    <measurement group_id="B2" value="27"/>
                    <measurement group_id="B3" value="93"/>
                    <measurement group_id="B4" value="30"/>
                    <measurement group_id="B5" value="247"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="58.4" spread="9.51"/>
                    <measurement group_id="B2" value="59.2" spread="8.63"/>
                    <measurement group_id="B3" value="57.9" spread="10.1"/>
                    <measurement group_id="B4" value="58.0" spread="9.14"/>
                    <measurement group_id="B5" value="58.3" spread="9.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="174"/>
                    <measurement group_id="B2" value="50"/>
                    <measurement group_id="B3" value="164"/>
                    <measurement group_id="B4" value="55"/>
                    <measurement group_id="B5" value="443"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="142"/>
                    <measurement group_id="B2" value="52"/>
                    <measurement group_id="B3" value="136"/>
                    <measurement group_id="B4" value="48"/>
                    <measurement group_id="B5" value="378"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percent Change From Baseline Low Density Lipoprotein-cholesterol (LDL-C) at Week 12</title>
        <time_frame>Baseline to 12 weeks</time_frame>
        <population>All patients, irrespective of protocol violations, who had Week 12 measurements, whether on drug or not.</population>
        <group_list>
          <group group_id="O1">
            <title>Pitavastatin 2 mg QD</title>
            <description>Pitavastatin 2 mg daily</description>
          </group>
          <group group_id="O2">
            <title>Atorvastatin 10 mg QD</title>
            <description>Atorvastatin 10 mg daily</description>
          </group>
          <group group_id="O3">
            <title>Pitavastatin 4 mg QD</title>
            <description>Pitavastatin 4 mg daily</description>
          </group>
          <group group_id="O4">
            <title>Atorvastatin 20 mg QD</title>
            <description>Atorvastatin 20 mg daily</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline Low Density Lipoprotein-cholesterol (LDL-C) at Week 12</title>
          <population>All patients, irrespective of protocol violations, who had Week 12 measurements, whether on drug or not.</population>
          <units>percent change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="301"/>
                <count group_id="O2" value="98"/>
                <count group_id="O3" value="288"/>
                <count group_id="O4" value="100"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-37.89" spread="13.841"/>
                    <measurement group_id="O2" value="-38.76" spread="14.582"/>
                    <measurement group_id="O3" value="-45.5" spread="14.005"/>
                    <measurement group_id="O4" value="-43.9" spread="15.853"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in Total Cholesterol (TC)</title>
        <description>Percent change in total cholesterol from baseline to Week 12</description>
        <time_frame>Baseline to 12 Weeks</time_frame>
        <population>All patients, irrespective of protocol violations, who had Week 12 measurements, whether on drug or not.</population>
        <group_list>
          <group group_id="O1">
            <title>Pitavastatin 2 mg QD</title>
            <description>Pitavastatin 2 mg daily</description>
          </group>
          <group group_id="O2">
            <title>Atorvastatin 10 mg QD</title>
            <description>Atorvastatin 10 mg daily</description>
          </group>
          <group group_id="O3">
            <title>Pitavastatin 4 mg QD</title>
            <description>Pitavastatin 4 mg daily</description>
          </group>
          <group group_id="O4">
            <title>Atorvastatin 20 mg QD</title>
            <description>Atorvastatin 20 mg daily</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Total Cholesterol (TC)</title>
          <description>Percent change in total cholesterol from baseline to Week 12</description>
          <population>All patients, irrespective of protocol violations, who had Week 12 measurements, whether on drug or not.</population>
          <units>percent change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="301"/>
                <count group_id="O2" value="98"/>
                <count group_id="O3" value="288"/>
                <count group_id="O4" value="100"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-27.57" spread="10.359"/>
                    <measurement group_id="O2" value="-28.92" spread="11.441"/>
                    <measurement group_id="O3" value="-33.09" spread="10.732"/>
                    <measurement group_id="O4" value="-32.99" spread="12.073"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in High Density Lipoprotein Cholesterol (HDL-C)</title>
        <description>percent change from baseline in high density lipoprotein-cholesterol (HDL-C)</description>
        <time_frame>Baseline to 12 weeks</time_frame>
        <population>All patients, irrespective of protocol violations, who had Week 12 measurements, whether on drug or not.</population>
        <group_list>
          <group group_id="O1">
            <title>Pitavastatin 2 mg QD</title>
            <description>Pitavastatin 2 mg daily</description>
          </group>
          <group group_id="O2">
            <title>Atorvastatin 10 mg QD</title>
            <description>Atorvastatin 10 mg daily</description>
          </group>
          <group group_id="O3">
            <title>Pitavastatin 4 mg QD</title>
            <description>Pitavastatin 4 mg daily</description>
          </group>
          <group group_id="O4">
            <title>Atorvastatin 20 mg QD</title>
            <description>Atorvastatin 20 mg daily</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in High Density Lipoprotein Cholesterol (HDL-C)</title>
          <description>percent change from baseline in high density lipoprotein-cholesterol (HDL-C)</description>
          <population>All patients, irrespective of protocol violations, who had Week 12 measurements, whether on drug or not.</population>
          <units>percent change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="301"/>
                <count group_id="O2" value="98"/>
                <count group_id="O3" value="288"/>
                <count group_id="O4" value="100"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.28" spread="16.501"/>
                    <measurement group_id="O2" value="3.42" spread="16.820"/>
                    <measurement group_id="O3" value="4.93" spread="16.629"/>
                    <measurement group_id="O4" value="2.63" spread="13.803"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>TC:HDL-C Ratio</title>
        <description>Ratio of mean total cholesterol to mean HDL-C at 12 weeks</description>
        <time_frame>12 weeks</time_frame>
        <population>All patients, irrespective of protocol violations, who had Week 12 measurements, whether on drug or not.</population>
        <group_list>
          <group group_id="O1">
            <title>Pitavastatin 2 mg QD</title>
            <description>Pitavastatin 2 mg daily</description>
          </group>
          <group group_id="O2">
            <title>Atorvastatin 10 mg QD</title>
            <description>Atorvastatin 10 mg daily</description>
          </group>
          <group group_id="O3">
            <title>Pitavastatin 4 mg QD</title>
            <description>Pitavastatin 4 mg daily</description>
          </group>
          <group group_id="O4">
            <title>Atorvastatin 20 mg QD</title>
            <description>Atorvastatin 20 mg daily</description>
          </group>
        </group_list>
        <measure>
          <title>TC:HDL-C Ratio</title>
          <description>Ratio of mean total cholesterol to mean HDL-C at 12 weeks</description>
          <population>All patients, irrespective of protocol violations, who had Week 12 measurements, whether on drug or not.</population>
          <units>ratio</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="301"/>
                <count group_id="O2" value="98"/>
                <count group_id="O3" value="288"/>
                <count group_id="O4" value="100"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.018" spread="1.1294"/>
                    <measurement group_id="O2" value="3.763" spread="0.8667"/>
                    <measurement group_id="O3" value="3.583" spread="1.0961"/>
                    <measurement group_id="O4" value="3.79" spread="1.2052"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Triglycerides (TG)</title>
        <description>mean triglycerides at 12 weeks</description>
        <time_frame>12 weeks</time_frame>
        <population>All patients, irrespective of protocol violations, who had Week 12 measurements, whether on drug or not.</population>
        <group_list>
          <group group_id="O1">
            <title>Pitavastatin 2 mg QD</title>
            <description>Pitavastatin 2 mg daily</description>
          </group>
          <group group_id="O2">
            <title>Atorvastatin 10 mg QD</title>
            <description>Atorvastatin 10 mg daily</description>
          </group>
          <group group_id="O3">
            <title>Pitavastatin 4 mg QD</title>
            <description>Pitavastatin 4 mg daily</description>
          </group>
          <group group_id="O4">
            <title>Atorvastatin 20 mg QD</title>
            <description>Atorvastatin 20 mg daily</description>
          </group>
        </group_list>
        <measure>
          <title>Triglycerides (TG)</title>
          <description>mean triglycerides at 12 weeks</description>
          <population>All patients, irrespective of protocol violations, who had Week 12 measurements, whether on drug or not.</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="302"/>
                <count group_id="O2" value="98"/>
                <count group_id="O3" value="288"/>
                <count group_id="O4" value="100"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="132.4" spread="59.82"/>
                    <measurement group_id="O2" value="122.2" spread="57.09"/>
                    <measurement group_id="O3" value="124.4" spread="64.91"/>
                    <measurement group_id="O4" value="122.6" spread="59.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Non-HDL:HDL Ratio</title>
        <description>Ratio of non-HDL to HDL at 12 weeks</description>
        <time_frame>12 weeks</time_frame>
        <population>All patients, irrespective of protocol violations, who had Week 12 measurements, whether on drug or not.</population>
        <group_list>
          <group group_id="O1">
            <title>Pitavastatin 2 mg QD</title>
            <description>Pitavastatin 2 mg daily</description>
          </group>
          <group group_id="O2">
            <title>Atorvastatin 10 mg QD</title>
            <description>Atorvastatin 10 mg daily</description>
          </group>
          <group group_id="O3">
            <title>Pitavastatin 4 mg QD</title>
            <description>Pitavastatin 4 mg daily</description>
          </group>
          <group group_id="O4">
            <title>Atorvastatin 20 mg QD</title>
            <description>Atorvastatin 20 mg daily</description>
          </group>
        </group_list>
        <measure>
          <title>Non-HDL:HDL Ratio</title>
          <description>Ratio of non-HDL to HDL at 12 weeks</description>
          <population>All patients, irrespective of protocol violations, who had Week 12 measurements, whether on drug or not.</population>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="234"/>
                <count group_id="O2" value="82"/>
                <count group_id="O3" value="250"/>
                <count group_id="O4" value="82"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.993" spread="1.0935"/>
                    <measurement group_id="O2" value="2.770" spread="0.8846"/>
                    <measurement group_id="O3" value="2.601" spread="1.0961"/>
                    <measurement group_id="O4" value="2.710" spread="1.1771"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Apolipoprotein B (Apo B)</title>
        <description>Apolipoprotein B at 12 weeks</description>
        <time_frame>12 weeks</time_frame>
        <population>All patients, irrespective of protocol violations, who had Week 12 measurements, whether on drug or not.</population>
        <group_list>
          <group group_id="O1">
            <title>Pitavastatin 2 mg QD</title>
            <description>Pitavastatin 2 mg daily</description>
          </group>
          <group group_id="O2">
            <title>Atorvastatin 10 mg QD</title>
            <description>Atorvastatin 10 mg daily</description>
          </group>
          <group group_id="O3">
            <title>Pitavastatin 4 mg QD</title>
            <description>Pitavastatin 4 mg daily</description>
          </group>
          <group group_id="O4">
            <title>Atorvastatin 20 mg QD</title>
            <description>Atorvastatin 20 mg daily</description>
          </group>
        </group_list>
        <measure>
          <title>Apolipoprotein B (Apo B)</title>
          <description>Apolipoprotein B at 12 weeks</description>
          <population>All patients, irrespective of protocol violations, who had Week 12 measurements, whether on drug or not.</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="295"/>
                <count group_id="O2" value="98"/>
                <count group_id="O3" value="285"/>
                <count group_id="O4" value="99"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="114.5" spread="23.36"/>
                    <measurement group_id="O2" value="111.1" spread="25.12"/>
                    <measurement group_id="O3" value="102.3" spread="22.04"/>
                    <measurement group_id="O4" value="102.4" spread="22.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Apolipoprotein-A1 (Apo-A1)</title>
        <description>Apolipoprotein-A1 at 12 weeks</description>
        <time_frame>12 weeks</time_frame>
        <population>All patients, irrespective of protocol violations, who had Week 12 measurements, whether on drug or not.</population>
        <group_list>
          <group group_id="O1">
            <title>Pitavastatin 2 mg QD</title>
            <description>Pitavastatin 2 mg daily</description>
          </group>
          <group group_id="O2">
            <title>Atorvastatin 10 mg QD</title>
            <description>Atorvastatin 10 mg daily</description>
          </group>
          <group group_id="O3">
            <title>Pitavastatin 4 mg QD</title>
            <description>Pitavastatin 4 mg daily</description>
          </group>
          <group group_id="O4">
            <title>Atorvastatin 20 mg QD</title>
            <description>Atorvastatin 20 mg daily</description>
          </group>
        </group_list>
        <measure>
          <title>Apolipoprotein-A1 (Apo-A1)</title>
          <description>Apolipoprotein-A1 at 12 weeks</description>
          <population>All patients, irrespective of protocol violations, who had Week 12 measurements, whether on drug or not.</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="295"/>
                <count group_id="O2" value="98"/>
                <count group_id="O3" value="285"/>
                <count group_id="O4" value="99"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="164.6" spread="29.10"/>
                    <measurement group_id="O2" value="166" spread="26.8"/>
                    <measurement group_id="O3" value="166.9" spread="28.01"/>
                    <measurement group_id="O4" value="160.9" spread="26.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Apo-B:Apo-A1 Ratio</title>
        <description>Ratio of Apo-B to Apo-A1 at 12 weeks</description>
        <time_frame>12 weeks</time_frame>
        <population>All patients, irrespective of protocol violations, who had Week 12 measurements, whether on drug or not.</population>
        <group_list>
          <group group_id="O1">
            <title>Pitavastatin 2 mg QD</title>
            <description>Pitavastatin 2 mg daily</description>
          </group>
          <group group_id="O2">
            <title>Atorvastatin 10 mg QD</title>
            <description>Atorvastatin 10 mg daily</description>
          </group>
          <group group_id="O3">
            <title>Pitavastatin 4 mg QD</title>
            <description>Pitavastatin 4 mg daily</description>
          </group>
          <group group_id="O4">
            <title>Atorvastatin 20 mg QD</title>
            <description>Atorvastatin 20 mg daily</description>
          </group>
        </group_list>
        <measure>
          <title>Apo-B:Apo-A1 Ratio</title>
          <description>Ratio of Apo-B to Apo-A1 at 12 weeks</description>
          <population>All patients, irrespective of protocol violations, who had Week 12 measurements, whether on drug or not.</population>
          <units>ratio</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="295"/>
                <count group_id="O2" value="98"/>
                <count group_id="O3" value="285"/>
                <count group_id="O4" value="99"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.72" spread="0.228"/>
                    <measurement group_id="O2" value="0.68" spread="0.181"/>
                    <measurement group_id="O3" value="0.64" spread="0.198"/>
                    <measurement group_id="O4" value="0.66" spread="0.205"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>High Sensitivity C-reactive Protein (Hs-CRP) at 12 Weeks</title>
        <description>high sensitivity C-reactive protein (hs-CRP) at 12 weeks</description>
        <time_frame>12 weeks</time_frame>
        <population>All patients, irrespective of protocol violations, who had Week 12 measurements, whether on drug or not.</population>
        <group_list>
          <group group_id="O1">
            <title>Pitavastatin 2 mg QD</title>
            <description>Pitavastatin 2 mg daily</description>
          </group>
          <group group_id="O2">
            <title>Atorvastatin 10 mg QD</title>
            <description>Atorvastatin 10 mg daily</description>
          </group>
          <group group_id="O3">
            <title>Pitavastatin 4 mg QD</title>
            <description>Pitavastatin 4 mg daily</description>
          </group>
          <group group_id="O4">
            <title>Atorvastatin 20 mg QD</title>
            <description>Atorvastatin 20 mg daily</description>
          </group>
        </group_list>
        <measure>
          <title>High Sensitivity C-reactive Protein (Hs-CRP) at 12 Weeks</title>
          <description>high sensitivity C-reactive protein (hs-CRP) at 12 weeks</description>
          <population>All patients, irrespective of protocol violations, who had Week 12 measurements, whether on drug or not.</population>
          <units>mg/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="301"/>
                <count group_id="O2" value="97"/>
                <count group_id="O3" value="288"/>
                <count group_id="O4" value="100"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.87" spread="5.101"/>
                    <measurement group_id="O2" value="2.39" spread="3.053"/>
                    <measurement group_id="O3" value="3.12" spread="5.186"/>
                    <measurement group_id="O4" value="2.56" spread="2.958"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Oxidized LDL at 12 Weeks</title>
        <description>oxidized low density lipoprotein at 12 weeks</description>
        <time_frame>12 weeks</time_frame>
        <population>All patients, irrespective of protocol violations, who had Week 12 measurements, whether on drug or not.</population>
        <group_list>
          <group group_id="O1">
            <title>Pitavastatin 2 mg QD</title>
            <description>Pitavastatin 2 mg daily</description>
          </group>
          <group group_id="O2">
            <title>Atorvastatin 10 mg QD</title>
            <description>Atorvastatin 10 mg daily</description>
          </group>
          <group group_id="O3">
            <title>Pitavastatin 4 mg QD</title>
            <description>Pitavastatin 4 mg daily</description>
          </group>
          <group group_id="O4">
            <title>Atorvastatin 20 mg QD</title>
            <description>Atorvastatin 20 mg daily</description>
          </group>
        </group_list>
        <measure>
          <title>Oxidized LDL at 12 Weeks</title>
          <description>oxidized low density lipoprotein at 12 weeks</description>
          <population>All patients, irrespective of protocol violations, who had Week 12 measurements, whether on drug or not.</population>
          <units>U/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="302"/>
                <count group_id="O2" value="98"/>
                <count group_id="O3" value="289"/>
                <count group_id="O4" value="100"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="59.93" spread="14.96"/>
                    <measurement group_id="O2" value="58.59" spread="14.679"/>
                    <measurement group_id="O3" value="54.32" spread="13.496"/>
                    <measurement group_id="O4" value="54.70" spread="17.865"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>National Cholesterol Education Program [NCEP]LDL-C Target Attainment</title>
        <description>Number of patients achieving NCEP LDL-C target (LDL-C less than or equal to 130 mg/dL)</description>
        <time_frame>up to 12 weeks</time_frame>
        <population>All patients, irrespective of protocol violations, who had Week 12 measurements, whether on drug or not.</population>
        <group_list>
          <group group_id="O1">
            <title>Pitavastatin 2 mg QD</title>
            <description>Pitavastatin 2 mg daily</description>
          </group>
          <group group_id="O2">
            <title>Atorvastatin 10 mg QD</title>
            <description>Atorvastatin 10 mg daily</description>
          </group>
          <group group_id="O3">
            <title>Pitavastatin 4 mg QD</title>
            <description>Pitavastatin 4 mg daily</description>
          </group>
          <group group_id="O4">
            <title>Atorvastatin 20 mg QD</title>
            <description>Atorvastatin 20 mg daily</description>
          </group>
        </group_list>
        <measure>
          <title>National Cholesterol Education Program [NCEP]LDL-C Target Attainment</title>
          <description>Number of patients achieving NCEP LDL-C target (LDL-C less than or equal to 130 mg/dL)</description>
          <population>All patients, irrespective of protocol violations, who had Week 12 measurements, whether on drug or not.</population>
          <units>Patients</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="315"/>
                <count group_id="O2" value="102"/>
                <count group_id="O3" value="298"/>
                <count group_id="O4" value="102"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="179"/>
                    <measurement group_id="O2" value="67"/>
                    <measurement group_id="O3" value="232"/>
                    <measurement group_id="O4" value="72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>Safety was assessed for all randomized patients who received at least one dose of study drug (Safety Population). The Safety Population contained 821 patients; 616 were treated with pitavastatin and 205 with atorvastatin.</desc>
      <group_list>
        <group group_id="E1">
          <title>Pitavastatin 2 mg QD</title>
          <description>Pitavastatin 2 mg daily</description>
        </group>
        <group group_id="E2">
          <title>Atorvastatin 10 mg QD</title>
          <description>Atorvastatin 10 mg daily</description>
        </group>
        <group group_id="E3">
          <title>Pitavastatin 4 mg QD</title>
          <description>Pitavastatin 4 mg daily</description>
        </group>
        <group group_id="E4">
          <title>Atorvastatin 20 mg QD</title>
          <description>Atorvastatin 20 mg daily</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA8.1</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="316"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="102"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="300"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="103"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>acute myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="103"/>
              </event>
              <event>
                <sub_title>angina pectoris</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="103"/>
              </event>
              <event>
                <sub_title>angina unstable</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="316"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="102"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="103"/>
              </event>
              <event>
                <sub_title>myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="300"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="103"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>deafness neurosensory</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="103"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>burning sensation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="103"/>
              </event>
              <event>
                <sub_title>encephalopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="103"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>abortion spontaneous</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="103"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title vocab="MedDRA 8.1">pruritus generalized</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="103"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>2</frequency_threshold>
        <default_vocab>MedDRA8.1</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="316"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="102"/>
                <counts group_id="E3" subjects_affected="17" subjects_at_risk="300"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="103"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>constipation</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="316"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="102"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="300"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="103"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="316"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="102"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="300"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="103"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>myalgia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="316"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="102"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="300"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="103"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr Neil Hounslow</name_or_title>
      <organization>Kowa Research Europe, Ltd.</organization>
      <phone>+44 118 922 9004</phone>
      <email>nhounslow@kowa.co.uk</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

